(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 18.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Karyopharm Therapeutics's revenue in 2024 is $146,033,000.On average, 4 Wall Street analysts forecast KPTI's revenue for 2024 to be $17,074,229,111, with the lowest KPTI revenue forecast at $16,569,659,952, and the highest KPTI revenue forecast at $17,357,869,471. On average, 4 Wall Street analysts forecast KPTI's revenue for 2025 to be $20,302,090,923, with the lowest KPTI revenue forecast at $16,281,992,245, and the highest KPTI revenue forecast at $24,131,868,647.
In 2026, KPTI is forecast to generate $29,096,553,010 in revenue, with the lowest revenue forecast at $28,309,954,430 and the highest revenue forecast at $30,361,600,520.